BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Intestine, Pharmacogenetics, Bleomycin, rs2476601, MDM2, Response to oxidative stress)
Bookmark Forward

QuickView for Tacrolimus (compound)


Genetic Markers

Most Correlated Genes

  1. ATF3
  2. NR4A3
  3. PPP3R1
  4. HLA-DQB1
  5. SERPINB2
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. PILON_KLF1_TARGETS_DN
  2. heterocyclic compound binding
  3. organic cyclic compound binding
  4. regulation of nitrogen compound metabolic process
  5. response to organic substance
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Wildtype yeast response to calcineurin inhibitor, Ca2+ or Na+
  2. PBMCs from cyclosporin, rapamycin, or tacrolimus treated patients with chronic allograft nephropathy
  3. Hearts of rats exposed variety of toxicants
  4. Macrophages pretreated with calcineurin inhibitor FK506 and infected with Aspergillus fumigatus
  5. Splenic long term dendritic D1 cell line treated with curdlan and immunosuppressant FK506
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicia…
  2. Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolo…
  3. Development of a predictive model for nephrotoxicity during tacrolimus treatment using machine learn…
  4. 308 nm excimer laser and tacrolimus ointment in the treatment of facial vitiligo: a systematic revie…
  5. Revisiting the nature and pharmacodynamics of tacrolimus metabolites.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Tacrolimus Pharmacokinetic Subpopulations
  2. Diabetogenicity of Cyclosporine and Tacrolimus
  3. Drug Interaction Study of Isavuconazole and Tacrolimus
  4. Tacrolimus for Malar Edema
  5. PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-rele…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.